INTRODUCTION
• Low-molecular-weight heparin (LMWH) is recommended as hemodialysis anticoagulation in the European Best Practice Guidelines 1 .
• LMWH doses are defined according to the patient weight for each manufacturer but reduced doses are more frequently used according to clotting of the extracorporeal circuit.
• There is not available data of factor Xa inhibition during or after hemodialysis treatment for each LMWH. Moreover, differences of formulation determine varying clearance for nonstandard hemodialysis (HD) schedules such as on-line hemodiaflitration (OL-HDF).
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METHODS
• Observational and retrospective study.
• Conducted in chronic hemodialysis patients of our unit HD who received a single bolus dose of bemiparin at the start of a dialysis.
• Doses had been defined according to clotting parameters of circuit.
• Measurements of anti-Xa activity were collected before start dialysis, 2 hours after beginning dialysis and at 20 min after finishing dialysis.
• The objective value of anti-Xa activity was >0.4 UI/ml during HD and less than 0.4 UI/ml after finishing dialysis (this level discarded anticoagulant effect).
• Data were registered from the midweek dialysis.
• Descriptive statistics and non parametric test (chi-square test and U-Mann Withney) were used (SPSS v22).
OBJETIVE
• To study the efficacy and safety of bemiparin as anticoagulant in HD and OL-HDF monitoring anti-Xa activity during and after both modalities of dialysis. Also, It was defined a proposal of dose recommendation.
CONCLUSIONS
Bemiparin is effective and secure for preventing clotting the circuit of hemodialysis in both therapy, conventional HD and OL-HDF. A mean dose of 50 UI/kg at the start of a dialysis could be proposed for HD and an increase of 10% of this dose could be proposed for OL-HDF. Both doses are similar to recommended doses for the manufacture as prophylactic antithrombotic therapy. Comparison of Mean anti-Xa activity between OL-HDF and HD ----baseline ----at 2 hours ----after 20 min of session OL-HDF HD
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